Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Discovery Platform
Sponsor : Bristol Myers Squibb
Deal Size : $285.0 million
Deal Type : Expanded Collaboration
Details : Under the expansion, Bristol Myers Squibb increases its access to a novel targeted protein degradation approach. The focus will be on selected targets that are relevant to a range of neurodegenerative conditions.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 01, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Discovery Platform
Sponsor : Bristol Myers Squibb
Deal Size : $285.0 million
Deal Type : Expanded Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Discovery Platform
Sponsor : Biogen
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Cevec Announces New License Agreement for Its Aav Manufacturing Technology Elevecta® IN Gene Therapy
Details : Under the terms of the agreement, CEVEC grants Biogen a non-exclusive license for CEVEC’s ELEVECTA® Technology. The deal will afford Biogen the rights to use the technology across their portfolio of gene therapy products.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
August 01, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Discovery Platform
Sponsor : Biogen
Deal Size : Undisclosed
Deal Type : Licensing Agreement